arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Benitec Biopharma Inc.

BNTC

$13.13 ▲ +0.56 (+4.41%) at close

8 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Benitec Biopharma Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $475.4M

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -33.9% ↗

FCF / Share $-0.65 ↗

Trailing P/E —

Price / Book 3.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 6, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-37.92M

↓ -74.3% —

FCF / Share Free cash flow per share

$-0.65

↑ +86.5% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗	FY 2019 Jun 30, 2019 10-K ↗	FY 2018 Jun 30, 2018 10-K ↗
Revenue Growth YoY (%)	—	N/M	2.7% Caution ↑ Caution Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-66%)	23.7% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+197%)	-42.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-627%)	-99.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1340%)	—	—
EPS Growth YoY (%)	80.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	61.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-533.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	31.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-74.3% Weak ↓ Weak Declining Year-over-year change in net income	-11.2% Weak ↑ Weak Improving Year-over-year change in net income	-7.4% Weak ↑ Weak Improving Year-over-year change in net income	-31.2% Weak Weak Year-over-year change in net income	-67.8% Weak Weak Year-over-year change in net income	N/M	—	—
FCF Growth YoY (%)	86.5% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	62.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-567.5% Weak Weak Year-over-year change in free cash flow	35.9% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	—	—	-9.7% Weak Weak Compound annual revenue growth over 3 years	-81.8% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗	FY 2019 Jun 30, 2019 10-K ↗	FY 2018 Jun 30, 2018 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	—	21.2% Good Good Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+41%)	—
Profit Margin (%) (%)	—	—	—	—	—	—	21.4% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+78%)	—
FCF Margin (%) (%)	—	—	—	—	—	—	36.0% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.62x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.68x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗	FY 2019 Jun 30, 2019 10-K ↗	FY 2018 Jun 30, 2018 10-K ↗
Return on Invested Capital (%)	-33.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-37.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-7462.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-489.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-53.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-63.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	12.3% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-41.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-43.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-427.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-298.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-63.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-71.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	13.4% Good Good Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-39.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-360%)	-46.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-407%)	—	—	-69.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-563%)	-80.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-639%)	15.7% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: At sector avg	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗	FY 2019 Jun 30, 2019 10-K ↗	FY 2018 Jun 30, 2018 10-K ↗
Net Debt (USD)	$-97.74M	$-50.87M	$-2.48M	$-4.06M	$-19.77M	$-9.80M	$-15.72M	$-11.88M

📊 What does each share earn? 6 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗	FY 2019 Jun 30, 2019 10-K ↗	FY 2018 Jun 30, 2018 10-K ↗
Revenue per Share (USD)	—	$0.00	$0.05	$0.01	$0.01	—	—	—
Basic EPS, GAAP (USD)	$-1.05	$-5.51	$-14.12	$-2.23	$-3.23	—	—	—
Free Cash Flow per Share (USD)	$-0.65	$-4.82	$-13.00	$-1.95	$-3.04	—	—	—
Book Value per Share (USD)	$4.15	$28.27	$0.12	$0.35	$2.45	$9.24	$19.37	—
Tangible Book Value per Share (USD)	$4.15	$28.27	$0.12	$0.35	$2.45	$9.24	$19.37	—
Basic Weighted Avg Shares (shares)	36.21M	4.06M	1.39M	8.17M	4.30M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗	FY 2019 Jun 30, 2019 10-K ↗	FY 2018 Jun 30, 2018 10-K ↗
Working Capital (USD)	$96.72M	$46.75M	$-249.00K	$2.29M	$19.24M	$9.67M	$16.11M	—
Total Equity (USD)	$97.30M	$47.25M	$202.00K	$2.88M	$20.01M	$10.24M	$16.59M	$13.84M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Jun 30, 2025 10-K ↗	FY 2024 Jun 30, 2024 10-K ↗	FY 2023 Jun 30, 2023 10-K ↗	FY 2022 Jun 30, 2022 10-K ↗	FY 2021 Jun 30, 2021 10-K ↗	FY 2020 Jun 30, 2020 10-K ↗	FY 2019 Jun 30, 2019 10-K ↗	FY 2018 Jun 30, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	—	$0.00	$75.00K	$73.00K	$59.00K	$102.00K	$12.20M	—
Depreciation Expense (USD)	$66.00K	$87.00K	$136.00K	$167.00K	$231.00K	$190.00K	$158.00K	—
Net Income, GAAP (USD)	$-37.92M	$-21.75M	$-19.56M	$-18.21M	$-13.88M	$-8.27M	$2.61M	—
Operating Cash Flow (USD)	$-23.59M	$-19.40M	$-18.01M	$-15.90M	$-12.83M	$-7.54M	$4.79M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 29 quarters

Benitec Biopharma Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BNTC with peers